Email Print Share

News From the Field

Gold-standard clinical trials fail to capture how behavior changes influence treatment


June 10, 2015

This material is available primarily for archival purposes. Telephone numbers or other contact information may be out of date; please see current contact information at media contacts.

Double-blind clinical trials for new drugs are considered the "gold standard" of medical research but there's an important factor they don't take into account: How a medication's performance can vary based on patients' lifestyle choices, according to a new study in PLOS ONE. Researchers at Princeton University, the California Institute of Technology and Cambridge University propose a new trial design that can measure such interactions between behavior and treatment. Full Story

Source
Princeton University, Woodrow Wilson School of Public and International Affairs

The National Science Foundation (NSF) is an independent federal agency that supports fundamental research and education across all fields of science and engineering. In fiscal year (FY) 2017, its budget is $7.5 billion. NSF funds reach all 50 states through grants to nearly 2,000 colleges, universities and other institutions. Each year, NSF receives more than 48,000 competitive proposals for funding and makes about 12,000 new funding awards.

mail icon Get News Updates by Email 

Useful NSF Web Sites:
NSF Home Page: https://www.nsf.gov
NSF News: https://www.nsf.gov/news/
For the News Media: https://www.nsf.gov/news/newsroom.jsp
Science and Engineering Statistics: https://www.nsf.gov/statistics/
Awards Searches: https://www.nsf.gov/awardsearch/